Over the past ten years, MGC Diagnostics (MGCD) has given investors little reason to cheer, with uneven revenue growth and no cumulative net income. All of that may be about to change. As you can see in the two charts below, movements in the stock have had a long term correlation with sales growth. If new management can consistently drive sales higher, which we think it can, shares should follow.
MGC Diagnostics' product line consists of a series of devices that test the cardiorespiratory functions of patients. Early detection of cardiac and pulmonary issues can end up saving healthcare systems more money down the line. For this reason, we don't see...
Only subscribers can access this article, which is part of the PRO research library covering 3,581 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: